(5E)-5-[5-hydroxy-4-[(E)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (5E)-5-[5-hydroxy-4-[(E)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydro-1H-pentalen-2-ylidene]pentanoic acid
• 化学式: C₂₁H₃₄O₄
• 分子量: 350.5
• InChiKey: XZFRIPGNUQRGPI-BUVLTHAESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  25
• 可旋转键数：
  10
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.76
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• METHOD OF TREATING DERMATOLOGICAL DISORDERS
  申请人：Karnik Pratima

  公开号：US20090042909A1

  公开（公告）日：2009-02-12

  A method of treating a dermatological disorder in a subject includes the step of administering a therapeutically effective amount of at least one PPARγ agonist or derivative thereof to the subject.
• Methods and compositions for treating inflammation
  申请人：Davis Pamela B.

  公开号：US20090118337A1

  公开（公告）日：2009-05-07

  A method of treating a subject with a cystic fibrosis related disorder includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof.
• METHODS AND COMPOSITIONS FOR TREATING CENTRAL NERVOUS SYSTEM TUMORS
  申请人：Landreth Gary E.

  公开号：US20100022600A1

  公开（公告）日：2010-01-28

  A method of treating a central nervous system tumor in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the tumor in the subject.
• METHODS AND COMPOSITIONS FOR TREATING ISCHEMIC STROKE
  申请人：Landerth Gary E.

  公开号：US20100331330A1

  公开（公告）日：2010-12-30

  A method of treating a cerebrovascular accident in a subject includes administering a therapeutically effective amount of at least one PPARγ agonist or a derivative thereof to the subject after onset of ischemia sufficient to a cause the cerebrovascular accident and prior to reperfusion.
• RXR AGONIST COMPOUNDS AND METHODS
  申请人：Landreth Gary E.

  公开号：US20120115912A1

  公开（公告）日：2012-05-10

  A method of treating a PPARγ and/or RXR related disease or disorder in a subject includes adminstering to the subject an RXR agonist alone or in combination with a PPARγ agonist.